Table 2.
Association between the HER2 status and molecular EC classification.
| Cohort | Molecular Subgroup | |||||
|---|---|---|---|---|---|---|
| Total | POLEmut | MMRd | NSMP | P53 | p-Value | |
| n = 405 | n = 52 (12.8%) | n = 135 (33.3%) | n = 126 (31.1%) | n = 92 (22.7%) | ||
| PORTEC-3 | <0.0001 | |||||
| HER2-negative | 381 (94.1) | 52 (100.0) | 135 (100.0) | 125 (99.2) | 69 (75.0) | |
| HER2-positive | 24 (5.9) | 0 (0.0) | 0 (0.0) | 1 (0.8) | 23 (25.0) | |
| Total | POLEmut | MSI | CN-low | CN-high | p-Value | |
| n = 506 | n = 49 (9.7%) | n = 148 (29.2%) | n = 146 (28.9%) | n = 163 (32.3%) | ||
| UCEC TCGA PanCancer | <0.0001 | |||||
| Non-ERBB2-amplified | 481 (95.1) | 49 (100.0) | 148 (100.0) | 146 (100.0) | 138 (84.7) | |
| ERBB2-amplified | 25 (4.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 25 (15.3) | |
Abbreviations: POLEmut, POLE-(ultra-)mutated; MMRd, mismatch repair-deficient; NSMP, no specific molecular profile; p53abn, p53-abnormal; TCGA, the Cancer Genome Atlas; UCEC, uterine corpus endometrial carcinoma; MSI, microsatellite-unstable; CN-low, copy number-low; CN-high, copy number-high.